Roivant Sciences (ROIV) rose 18.8% to $41.48 on $1.0bn of turnover. It opened level with the previous close, so the whole move happened during the session.
That leaves the price near the top of its twelve-month band of $14.70 to $41.48 — 100% of the way up it. The peak itself came today on September 8, 2026, while the floor dates back to September 24, 2025, 249 sessions ago.
The stock is up 20.2% over five sessions, up 14.1% over a month, up 177.6% over the year. It closed above its thirty-day average price by 17.2%.
High to low, the session covered 9.9% of price — well beyond the 3.4% this stock averages over thirty sessions. The close held 75% of the way up the day's range into the bell.
Worth $24bn, the company sits 51 of 128 by size within healthcare. The sector as a whole finished -2.3%, leaning the other way.
Trading opened at $39.98, touched $42.50 at best and $38.41 at worst, and finished on $41.48 — 0.0% short of the $41.48 annual peak, 182.2% clear of the $14.70 annual floor.
Turnover of $1.0bn compares with $288m on an average session for this stock, so participation was well above its own norm. Against the year, today ranks between the +22.1% best and the -7.6% worst day.
Recent form leans positive: 16 of the last thirty sessions closed up against 12 down. Its strongest single day in the past year was +22.1% on February 6, 2026, its weakest -7.6% on August 28, 2026.
Its size-neighbours in the sector did not follow — Labcorp (LH) -0.6% and Incyte Genomics (INCY) -1.9% — which argues for something particular to this company. ROIV placed 111th of 986 on money traded.
This text was generated automatically from the closing data. It contains no forecasts and no investment advice — only what the numbers say. Do your own research.